Developing a diverse portfolio of vaccine candidates for Rift Valley Fever, Chikungunya and Ebola

Project description

Researchers ignore capitalism when it comes to three of the most threatening infectious diseases

The 2014-2016 Ebola crisis in West Africa sounded an alarm about the major shortcomings in global preparedness for serious epidemics and public health emergencies. The second annual World Health Organisation Blueprint list of 2018 identified eight diseases and pathogens with serious epidemic potential that lacked efficacious drugs and/or vaccines. Ebola virus disease (EVD) and Rift Valley fever (RVF) are among them. Chikungunya (CHIKV) was considered for inclusion and deemed a major health risk. These diseases favour low- and middle-income countries and market incentives for vaccine development are lacking. EU funding of the ECRC project is helping the Coalition for Epidemic Preparedness Innovation in Norway accelerate vaccine development to protect the health and economic well-being of millions.

Fields of science

• medical and health sciences › health sciences › infectious diseases › RNA viruses › ebola
• medical and health sciences › health sciences › public health
• medical and health sciences › basic medicine › pharmacology and pharmacy › pharmaceutical drugs › vaccines

Programme(s)

• H2020-EU.3.1.2. - Preventing disease

Topic(s)

• SGA-SC1-CEPI-2019 - Grant to the Coalition for Epidemic Preparedness Innovations (CEPI)

Call for proposal

H2020-SGA-SC1-CEPI-2019
See other projects for this call

Funding Scheme

SGA-CSA - Specific Grant agreement and Coordination and Support Action

Coordinator

COALITION FOR EPIDEMIC PREPAREDNESS INNOVATION

Address

Marcus Thranses Gate 2
0473 Oslo
Norway

Activity type

Research Organisations

EU contribution

€ 36 000 000